NEW YORK --(BUSINESS WIRE)--Oct. 5, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that, on October 1, 2020 , the Compensation
PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 10, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will present at the following
Diversity of Experience Brings New Insight and Proven Leadership to Support Advanced Commercial Structure While Balancing Continuity in Key Positions Molly Henderson Named Chief Financial Officer Jason Smith Named General Counsel and Chief Compliance Officer Polly A.
NEW YORK --(BUSINESS WIRE)--Sep. 4, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units
Trial Did Not Meet Primary Endpoint Believed to be the Result of BOTOX Not Effectively Permeating the Urothelium RTGel Delivered Treatment to the Bladder as Expected with Dwell Time of Up to 10 Hours UroGen and AbbVie will Continue to Explore Use of the RTGel Hydrogel Formulation with AbbVie’s
Received U.S. FDA Approval of Jelmyto ® , the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) Successfully Commenced Launch of Jelmyto on June 1 st as Planned; Initial Commercial Performance Demonstrates Strong Execution Announced Positive
Conference Call and Webcast Scheduled for Monday, August 10, 2020 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Aug. 3, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases, today announced
PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 5, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock
PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 1, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett , President and Chief Executive Officer,
65% Complete Response in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer Of Patients who Achieved a Complete Response and Underwent an Evaluation at Each Timepoint, 97%, 86% and 85% Remained Disease Free at Six, Nine and 12 Months Following Initiation of Therapy,
